阿尔茨海默病的放射性分子显像探针研究进展

郭喆; 张锦明

郭喆 , 张锦明

文章导航 > 国际放射医学核医学杂志 > 2006, 30 > 4: (199-202)

引用本文:

Citation:

阿尔茨海默病的放射性分子显像探针研究进展

郭喆,
张锦明^,

100853 北京, 解放军总医院核医学科

通讯作者: 张锦明, zhangjm301@yahoo.com.cn

中图分类号: R817.4

Study on radioactive labeling of molecular probes for Alzheimer's disease

GUO Zhe,
ZHANG Jin-ming^,

Department of Nuclear Medicine, The PLA General Hospital, Beijing 100853, China

Corresponding author: ZHANG Jin-ming, zhangjm301@yahoo.com.cn

CLC number: R817.4

摘要: 阿尔茨海默病(AD)是引起痴呆的最常见类型之一,其主要病理改变包括由β-淀粉样蛋白构成的老年斑、神经原纤维缠结。在体观察AD脑内的β-淀粉样蛋白沉积,可为AD的诊断、疗效观察和治疗药物的研究提供很大帮助。目前已合成数种标记β-淀粉样蛋白的放射性探针并开始用于PET对AD患者脑内老年斑的在体显像研究,并显示出潜在的临床应用价值。AD的放射性分子显像探针仍需进一步研究,使其不仅适用于PET,而且还可以满足SPECT的显像要求。
- 阿尔茨海默病 /
- 老年斑 /
- β-淀粉样蛋白 /
- 体层摄影术,发射型计算机
Abstract: Alzheimer's disease (AD) is the most common form of dementia, the pathological features of AD include neuritic plaques composed of beta-amyloid protein, neurofibrillary tangles. Direct imaging of amyloid load in patients with AD in vivo would be useful for the early diagnosis of AD and the development and assessment of new treatment strategies. Different strategies are being used to develop compounds suitable for in vivo imaging of amyloid deposits in human brains. Two compounds, ¹⁸F-FDDNP and ¹¹C-PIB, both show more binding in the brains of patients with AD than in those of healthy people. Additional compounds will probably be developed that are suitable not only for PET but also for single photon emission CT (SPECT).
- Alzheimer's disease /
- Senile plaques /
- β-amyloid protein /
- Tomo emission computed
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	盛树力.老年性痴呆:从分子生物学到临床诊治.北京:科学技术出版社,1998.61-73.
[2]	Jarrett JT,Berger EP,Lansbury PT Jr,et al.The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation:implications for the pathogenesis of Alzheimer's disease.Biochemistry,1993,32(18):4693-4697.
[3]	Wisiniewski TM,Wadghiri YZ.Detection of Alzheimer's amyloid by magnetic resonance imaging.Proceedings of the Society for Neuroscience,31st Annual Meeting,2001.
[4]	Friedland RP,Kalaria R,Berridge M,et al.Neuroimaging of vessel amyloid in Alzheimer's disease.Ann NY Acad Sci,1997,826:242-247.
[5]	Zhuang ZP,Kung MP,Hou C,et al.Radioiodinated styrylbenzenes and thio flavins as probes for amyloid aggregates.J Med Chem,2001,44(12):1905-1914.
[6]	Mathis CA,Holt DP.In vivo evalution and imaging of a lipohilic derivative of Congo red for amyloid assessment.J Nucl Med,2001,42:252.
[7]	Klunk WE,Bacskai BJ,Mathis CA,et al.Imaging amyloid-beta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04,a systemically administered Congo red derivative.J Neuropathol Exp Neurol,2002,61(9):797-805.
[8]	Klunk WE,Wang Y,Huang GF,et al.Uncharged thioflavin-t derivatives bind to amyloid-beta protein with high affinity and readily enter the brain.Life Sci,2001,69(13):1471-1484.
[9]	Kung MP,Hou C,Zhuang ZP,et al.IMPY:an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques.Brain Res.2002,956(2):202-210.
[10]	Zhuang ZP,Kung MP,Wilson A,et al.Structure-activity relationship of imidazo[1,2-a] pyridines as ligands for detecting β-amyloid plaques in the brain.J Med Chem,2003,46(2):237-243.
[11]	Agdeppa ED,Kepe V,Liu J,et al.Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethyl-idene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer'sdisease.J Neurosci,2001,21(24):RC189.
[12]	Agdeppa ED,Kepe V,Liu J,et al.2-Dialky lamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs):novel diagnostic and therapeutic tools in Alzheimer's disease.Mol Imaging Biol,2003,5(6):404-417.
[13]	Shoghi-Jadid K,Small GW,Agdeppa ED,et al.Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease.Am J Geriatr Psychiatry,2002,10(1):24-35.
[14]	Jagust W.The proteomics of positron emission tomography.Ann Neurol,2004,55(3):303-305.
[15]	Klunk WE,Engler H,Nordberg A,et al.Imaging brain amyloid in Alzheimer's disease with pittsburgh compound-B.Ann Neurol,2004,55(3):306-319.
[16]	Schmitt FA,Davis DG,Wekstein DR,et al."Preclinical" AD revisited: neuropathology of cognitively normal older adults.Neurology,2000,55(3):370-376.

[1]	蔡汉成 , 尹端沚 , 张岚 , 李谷才 , 郑明强 , 汪勇先 . 早期诊断阿尔茨海默病的PET分子探针. 国际放射医学核医学杂志, 2006, 30(4): 202-205.
[2]	张冰 , 徐俊 , 徐运 , 朱斌 . fMRI在阿尔茨海默病、额颞叶痴呆及路易体痴呆中的研究进展. 国际放射医学核医学杂志, 2010, 34(5): 303-307. doi: 10.3760/cma.j.issn.1673-4114.2010.05.015
[3]	王瑞民 . 阿尔茨海默病等痴呆疾病的脑功能影像学研究. 国际放射医学核医学杂志, 2001, 25(5): 209-212.
[4]	宗佳滨 , 兰晓莉 , 张永学 . 阿尔茨海默病分子影像探针的研究进展. 国际放射医学核医学杂志, 2022, 46(1): 35-41. doi: 10.3760/cma.j.cn121381-202101045-00129
[5]	李祖贵 . 轻度认知障碍的功能性神经影像学研究进展. 国际放射医学核医学杂志, 2006, 30(2): 76-79.
[6]	暴丽洁 , 赵子龙 , 苏宁 , 周茂荣 . MRI和PET显像在阿尔茨海默病早期诊断中的应用. 国际放射医学核医学杂志, 2023, 47(4): 249-253. doi: 10.3760/cma.j.cn121381-202211009-00288
[7]	王新艳 , 管一晖 . 阿尔茨海默病的影像学诊断进展. 国际放射医学核医学杂志, 2013, 37(1): 52-59. doi: 10.3760/cma.j.issn.1673-4114.2013.01.014
[8]	段小艺 , 李淼 , 王黎 , 李宏利 , 赵周社 , 郭佑民 . 阿尔茨海默病PET正电子药物应用与研究进展. 国际放射医学核医学杂志, 2014, 38(5): 318-322. doi: 10.3760/cma.j.issn.1673-4114.2014.05.010
[9]	贾路路 , 郭昆冈 , 唐红军 , 付巍 . 阿尔茨海默病相关正电子显像剂的研究进展. 国际放射医学核医学杂志, 2023, 47(3): 190-195. doi: 10.3760/cma.j.cn121381-202209012-00279
[10]	孔艳艳 , 管一晖 , 吴平 . PET分子探针在阿尔茨海默病早期诊断中的研究进展. 国际放射医学核医学杂志, 2012, 36(5): 257-263. doi: 10.3760/cma.j.issn.1673-4114.2012.05.001

点击查看大图

计量

文章访问数: 1443
HTML全文浏览量: 166
PDF下载量: 5

阿尔茨海默病的放射性分子显像探针研究进展

郭喆
张锦明^,

通讯作者: 张锦明, zhangjm301@yahoo.com.cn

100853 北京, 解放军总医院核医学科

收稿日期: 2005-10-14

关键词:

摘要: 阿尔茨海默病(AD)是引起痴呆的最常见类型之一,其主要病理改变包括由β-淀粉样蛋白构成的老年斑、神经原纤维缠结。在体观察AD脑内的β-淀粉样蛋白沉积,可为AD的诊断、疗效观察和治疗药物的研究提供很大帮助。目前已合成数种标记β-淀粉样蛋白的放射性探针并开始用于PET对AD患者脑内老年斑的在体显像研究,并显示出潜在的临床应用价值。AD的放射性分子显像探针仍需进一步研究,使其不仅适用于PET,而且还可以满足SPECT的显像要求。